Versant's new immunology biotech Santa Ana Bio snags Series A with GV, TPG partners on board
Prolific biotech investor Versant Ventures is brewing another startup, this time immunology player Santa Ana Bio, whose board includes partners from GV and TPG.
On its website, the California biotech says it has recently closed a Series A financing. An SEC filing from last month outlined plans for a $70 million round after seeking a $42 million equity raise in 2021.
The company, led by CEO Peter Emtage, declined an interview and said it will come out of stealth later this year.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.